CIK 0001390478 · Non-accelerated filer<br>Smaller reporting company
SELLAS Life Sciences Group, Inc.
Sign in to watch- Ticker
- SLS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6462005278
- Business address
- 7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036
- Former names
- GALENA BIOPHARMA, INC., Galena Biopharma, Inc., RXI PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-16 | Stergiou Angelos M. President and CEO | Grant or award | +1,065,000 | 1,759,183 | ||
| 2026-01-07 | Varian John Director | Grant or award | +50,000 | 72,900 | ||
| 2026-01-07 | VAN NOSTRAND ROBERT L Director | Grant or award | +50,000 | 82,900 | ||
| 2026-01-07 | SCHEINBERG DAVID A Director | Grant or award | +50,000 | 73,082 | ||
| 2026-01-07 | CICIC DRAGAN SVP, Chief Development Officer | Grant or award | +300,000 | 557,805 | ||
| 2026-01-07 | Burns John Thomas CFO | Grant or award | +300,000 | 554,327 | ||
| 2026-01-07 | Kalin Katherine Bach Director | Grant or award | +50,000 | 154,400 | ||
| 2026-01-07 | Wasman Jane Director | Grant or award | +50,000 | 92,900 | ||
| 2025-12-03 | CICIC DRAGAN SVP, Chief Development Officer | Other disposition | −63,800 | $1.50 | $96K | 257,805 |
| 2025-12-03 | Burns John Thomas CFO | Other disposition | −58,592 | $1.50 | $88K | 254,327 |
| 2025-12-03 | Stergiou Angelos M. President and CEO | Other disposition | −187,066 | $1.50 | $281K | 686,966 |
| 2025-11-19 | Kalin Katherine Bach Director | Purchase | +63,400 | $1.59 | $101K | 104,400 |
| 2025-06-12 | VAN NOSTRAND ROBERT L Director | Purchase | +10,000 | $1.48 | $15K | 20,400 |
| 2025-05-30 | Wasman Jane Director | Purchase | +20,000 | $1.69 | $34K | 30,400 |
| 2025-05-22 | Kalin Katherine Bach Director | Purchase | +20,000 | $1.80 | $36K | 41,000 |
| 2025-01-10 | Burns John Thomas CFO | Grant or award | +113,000 | 217,762 | ||
| 2025-01-10 | Burns John Thomas CFO | Grant or award | +81,300 | 299,062 | ||
| 2025-01-10 | Burns John Thomas CFO | Grant or award · Stock Option (Right to Buy) | +169,500 | 169,500 | ||
| 2025-01-10 | Stergiou Angelos M. President and CEO | Grant or award | +257,000 | 615,132 | ||
| 2025-01-10 | Stergiou Angelos M. President and CEO | Grant or award | +243,900 | 859,032 |
Page 1 of 8 · 141 trades